No Data
No Data
AstraZeneca's Blockbuster Drug Tagrisso Wins EU Nod for Non-small Cell Lung Cancer
AstraZeneca Obtains EU Approval for Tagrisso in Non-small Cell Lung Cancer Treatment
AstraZeneca's Tagrisso Gains EU Approval for Unresectable EGFR-Mutated Lung Cancer
Why Astrazeneca (AZN) Outpaced the Stock Market Today
AstraZeneca Hits 4-week Low
The prospects of European Medical Care stocks are complex, with USA policies and new drug trial results being the key factors.
After falling from a high position in the last few months of 2024, European Medical Care stocks face the risks of US politics and the results of high-risk new drug trials in the new year.
loading...
Just Care Bears : I thought there’s a FDA approval going on on this today no news yet
Claudius NJIE Just Care Bears : yes good news is coming.
Claudius NJIE : pls run to at least 50